Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer

ConclusionOur real-world study suggests that eribulin may be a potential treatment option for MBC patients who fail a prior PI3K inhibitor.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research